Full Press Release Details
| Dr. Reddy's Laboratories Ltd. | |
| 8-2-337, Road No. 3, Banjara Hills, | |
| Hyderabad - 500 034, Telangana, | |
| India. | |
| CIN : L85195TG1984PLC004507 | |
| Tel :+91 40 4900 2900 | |
| Fax :+91 40 4900 2999 | |
| Email :mail@drreddys.com | |
| www.drreddys.com |
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / 22722037 / 22722039 | Fax Nos.: 022-26598120/ 26598237/ 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed a Press Release on
"Dr. Reddy's Laboratories Announces Commercial Launch of 2DGTM."
This is for your information.
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | Investor relationS AMIT AGARWAL amita@drreddys.com | Media relationS Usha IYER ushaiyer@drreddys.com |
Reddy's Laboratories Announces Commercial Launch of 2DGTM
Hyderabad, India. June 28, 2021 -
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as "Dr.
Reddy's") today announced the commercial launch of 2-deoxy-D-glucose (2-DG).
Dr. Reddy's will supply to major
Government as well as private hospitals across India. In the initial weeks, the Company will make the drug available in hospitals
across metros and Tier 1 cities, and subsequently expand coverage to the rest of India.
2-DG manufactured by Dr. Reddy's
has a purity of 99.5% and is being sold commercially under the brand name 2DGTM. The maximum retail price (MRP) of
each sachet has been fixed at Rs. 990, with a subsidized rate offered to Government institutions. Enquiries for 2DGTM
can be sent to 2DG@drreddys.com.
2-DG was developed by the Institute of
Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration
with Dr. Reddy's. 2-DG is an oral drug. It can be administered only upon prescription and under the supervision of a qualified
physician to hospitalised moderate to severe COVID-19 patients as an adjunct therapy to the existing standard of care. Emergency
use approval for anti-COVID-19 therapeutic application of the drug was granted on May 1, 2021.
Dr. G. Satheesh Reddy, Secretary Department
of Defence (R&D) and Chairman, DRDO said: "We are pleased to have worked closely with our long-term industry partner
Dr. Reddy's Laboratories, Hyderabad, for testing 2-DG as therapeutic application in treatment of COVID-19 patients. DRDO has been
contributing in fight against COVID-19 pandemic with its spin off technologies."
Satish Reddy, Chairman, Dr. Reddy's
said: "2-DG is yet another addition to our COVID-19 portfolio that already covers the full spectrum of mild to moderate
and severe conditions and includes a vaccine. We are extremely pleased to have partnered with DRDO in our collective fight against
the COVID-19 pandemic."
About Dr. Reddy's: Dr. Reddy's
Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed
to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services &
Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas
of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates
in markets across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information,
log on to: www.drreddys.com
Disclaimer: This press release may include
statements of future expectations and other forward-looking statements that are based on the management's current views and
assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ
materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of
context, the words "may", "will", "should", "expects", "plans", "intends",
"anticipates", "believes", "estimates", "predicts", "potential", or "continue"
and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those
in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit
defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality
and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and
regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including
related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our
customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread
illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the
Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements"
sections of our Annual Report on Form 20-F for the year ended March 31, 2020. The company assumes no obligation to update any information